<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168167">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01907399</url>
  </required_header>
  <id_info>
    <org_study_id>Bonnotte PHRC IR 2010</org_study_id>
    <nct_id>NCT01907399</nct_id>
  </id_info>
  <brief_title>Study of Immune Response in Obesity and Type 2 Diabetes</brief_title>
  <acronym>IMMUNOBEDIA</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a link between activation of the immune response inducing chronic inflammation and
      both obesity and type 2 diabetes. To date, however, the cause(s) of this inflammation, the
      mechanisms of the inflammatory cascade and the type of cells involved are not completely
      known. The aim of our project is to study the principal cell types involved in the immune
      response from a quantitative and functional point of view in obese diabetic patients versus
      obese non-diabetic patients and healthy subjects who are neither diabetic nor obese.

      Despite possible inter-individual heterogeneity of immune cells, the fact that this work
      will be carried out by an accredited team with considerable expertise in the study of almost
      all the different types of immune cells will probably make it possible to know whether cell
      dysfunction and inflammation are associated with obesity or rather linked to insulin
      resistance. This study will be completed later by a second study on cell infiltration in
      adipose tissues in the 3 groups defined above. Better understanding of the physiopathology
      and especially the mechanisms and type of cells involved in obesity-related inflammation
      could quickly lead to the development of appropriate therapies that could act specifically
      on the cells involved and thus preclude the onset of complications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2010</start_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>quantification of Treg</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Obesity</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>obese patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>(BMI&gt; 30 kg/m2) androids (waist circumference&gt; 102 cm in men and&gt; 88 cm in woman)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>obese patients with type 2 diabetes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>(BMI&gt; 30 kg/m2) androids (waist circumference&gt; 102 cm in men and&gt; 88 cm in woman)with diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>free of disease inflammatory or infectious and will have a BMI &lt;25 Kg/m2et fasting glucose &lt;1g / L</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <arm_group_label>obese patients</arm_group_label>
    <arm_group_label>obese patients with type 2 diabetes</arm_group_label>
    <arm_group_label>healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient-control who have given written informed consent Patient-control who are
             covered by the National Health Insurance Agency Patient-control &gt; 18 years old

        The criteria to classify patients into groups will be as follows:

        Group 1- Obese diabetics BMI &gt; 30 Kg /m2 AND fasting glycemia &gt; 1.26 g/L AND Triglycerides
        &gt;1.5g/L AND HDL &lt;0.4g/L (men), &lt;0.5g/L (women) Group 2- Obese non-diabetics without
        metabolic syndrome BMI &gt; 30 Kg /m2 AND fasting glycemia &lt; 1.10 g/L AND Triglycerides
        &lt;1.5g/L AND HDL &gt;0.4g/L (men), &gt;0.5g/L (women) Group 3- Healthy Subjects BMI &lt; 25 Kg/m²
        AND fasting glycemia &lt; 1.10g/L AND Triglycerides &lt;1.5g/L

        Exclusion Criteria:

          -  Persons not covered by the National Health Insurance Agency Patients who presented a
             recent infection, or cancer or patients treated with corticosteroids or
             anti-inflammatory drugs. Patients with diabetes following an overload disease
             (hemochromatosis) or due to a disease of the pancreas Chronic infection Pregnant
             women Patients on the following treatments (glitazone: Actos, Avendia; GLP1 Agonist:
             Byetta, Victoza; Fibrates) Patients presenting severe renal insufficiency with
             clearance&lt;30ml/min
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>m CARPENTIER</last_name>
      <phone>03.80.29.35.10</phone>
      <email>maud.carpentier@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Bernard BONNOTTE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 24, 2013</lastchanged_date>
  <firstreceived_date>July 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obese patients</keyword>
  <keyword>obese patients with type 2 diabetes</keyword>
  <keyword>healthy volunteers</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
